Carex soap sales 40% higher than before Covid-19
PZ Cussons said that revenue is dropping compared to unusually high levels this time last year.
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Sales of Carex soap are still much higher than they were two years ago even as vaccines are rolled out across Europe and North America.
The maker of the soap, PZ Cussons, said on Wednesday that revenue from Carex is 40% higher than it was two years ago.
Yet the company has given back some of the gains its hygiene products, including Carex, made in the early days of the pandemic.
Over the three months to the end of August, revenue decreased by 9% compared to the same period in 2020, mainly because of its hygiene business.
We continue to navigate the well-publicised inflationary pressures on commodities and freight
Much of this can be traced back to Carex. This time last year there were very few discounted offers for customers to buy Carex as soap was in high demand.
Today discounting has returned to more normal levels.
Yet compared to this period before the pandemic two years ago revenue is 13% higher, PZ Cussons said.
“The medium-term outlook remains in line with our expectations and we have confidence that our brand and market portfolio will emerge strongly once we cycle through the unprecedented demand for hygiene products at the start of the pandemic,” said chief executive Jonathan Myers.
“We continue to navigate the well-publicised inflationary pressures on commodities and freight.”
The company returned to growth in August and expects this to continue throughout the second quarter of this financial year.
Mr Myers said that the company will bring low to mid single-digit revenue growth across the 12 months.
In the financial year ending in May, pre-tax profit grew 245% to £63.2 million on revenues of £603.3 million.
Mr Myers said: “This was set against a backdrop of the Covid-19 pandemic, which saw unprecedented levels of demand for hygiene products.
“Our brands were available for our consumers when they needed them most and we retained market leadership – both with Carex in the UK and Morning Fresh in Australia.
“We were also pleased with the strong performance of our baby and beauty businesses, as consumer hygiene habits start to normalise.”